Analysts expect BioLineRx Ltd. to report revenue of 371,467.52 for Q3 26, against a range of 347,444.34 to 395,490.70. The most recent reported quarter, Q2 26, came in at 294,000.00, a 39.4% miss against the 484,982.50 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 4.94 M | 11.75 M | 255,000.00 | 304,000.00 | 427,000.00 | 194,000.00 | 477,000.00 | 294,000.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 5.75 M | 8.50 M | 1.59 M | 675,023.57 | 1.02 M | 567,898.75 | 357,083.94 | 519,028.76 | 395,490.70 | 543,007.28 | 467,472.23 | 581,917.12 | 28,873.80 | 81,614.97 | 1.13 M | 2.69 M | ||||||||||
| Low Estimate | 5.37 M | 7.59 M | 1.47 M | 561,934.67 | 843,526.21 | 525,255.89 | 299,771.34 | 450,936.24 | 347,444.34 | 500,314.56 | 424,057.41 | 481,242.30 | 24,865.04 | 69,794.57 | 1.06 M | 2.37 M | ||||||||||
| Consensus Estimate | 5.56 M | 8.04 M | 1.53 M | 618,479.12 | 933,475.95 | 546,577.32 | 328,427.64 | 484,982.50 | 371,467.52 | 521,660.92 | 445,764.82 | 531,579.71 | 26,869.42 | 75,704.77 | 1.10 M | 2.53 M |
Analysts expect BioLineRx Ltd. to report earnings per share of -0.40 for Q3 26, against a range of -0.41 to -0.39. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | -1.60 | 0.00 | 0.00 | 0.00 | -0.27 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.53 | -0.79 | -0.81 | -0.32 | -0.58 | -0.38 | -0.98 | 0.00 | -0.39 | -0.36 | -0.12 | -0.16 | -0.34 | -0.45 | 0.22 | 0.18 | ||||||||||
| Low Estimate | -1.83 | -0.89 | -0.97 | -0.34 | -0.70 | -0.46 | -1.04 | 0.00 | -0.41 | -0.42 | -0.14 | -0.18 | -0.40 | -0.49 | 0.20 | 0.16 | ||||||||||
| Consensus Estimate | -1.68 | -0.84 | -0.89 | -0.33 | -0.64 | -0.42 | -1.01 | 0.00 | -0.40 | -0.39 | -0.13 | -0.17 | -0.37 | -0.47 | 0.21 | 0.17 |
Pull Wall Street consensus for BioLineRx Ltd. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=BLRX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "BLRX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=BLRX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();